Cambridge Epigenetix (also known as CEGX) is a bioscience company that uses epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw using the 5-hydroxymethylcytosine (5hmC) epigenetic modification. The company is utilizing technologies, often based on fundamental chemistry, to detect the epigenetic biomarkers that will be most useful in clinical settings.
|HQ||Little Chesterford, GB||Map|
|Employees (est.) (Sep 2019)||57||(+6%)|
Cambridge Epigenetix total Funding
Cambridge Epigenetix latest funding size
Time since last funding
|a year ago|
Cambridge Epigenetix investors
|Sequoia Capital, New Science Ventures, University of Cambridge Enterprise, Cambridge University, GV, Syncona Partners LLP., DNA Capital, Ahren Innovation Capital|
Net income (FY, 2012)
Pre tax profit
|GBP||FY, 2012||FY, 2013||FY, 2014||FY, 2015||FY, 2016||FY, 2017||FY, 2018|
Cambridge Epigenetix has 1.85k Twitter Followers. The number of followers has increased 0.6% month over month and increased 2.7% quarter over quarter
When was Cambridge Epigenetix founded?
Cambridge Epigenetix was founded in 2012.
Who are Cambridge Epigenetix key executives?
Cambridge Epigenetix's key executives are Shankar Balasubramian, Jason Mellad and Mike Booth.
How many employees does Cambridge Epigenetix have?
Cambridge Epigenetix has 57 employees.
Who are Cambridge Epigenetix competitors?
Competitors of Cambridge Epigenetix include Actinium Pharmaceuticals, Horizon Discovery and Quark Pharmaceuticals.
Where are Cambridge Epigenetix offices?
Cambridge Epigenetix has an office in Little Chesterford.
How many offices does Cambridge Epigenetix have?
Cambridge Epigenetix has 1 office.
Receive alerts for 300+ data fields across thousands of companies